The role of HIF prolyl hydroxylases in tumor progression and metastasis

• Antragsteller: Professor Dr. Georg Breier
• Fachliche Zuordnung: Pathologie
• Förderung: Förderung von 2006 bis 2012
• Projektkennung: Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 22095729

Hypoxia is a major driving force for tumor vascularization and progression. In mammalian cells, the transcriptional complex, hypoxia-inducuble factor (HIF), has emerged as a key regulator of physiological and pathological processes, mediating both local and systemic responses to hypoxia. HIF activity and stability, in turn, is tightly controlled through the enzymatic activity of prolyl and asparaginyl hydroxylases which serve as cellular oxygen sensors. While the role of HIF in activating the angiogenic program in tumor cells is well established, little is known about the role of hypoxia signalling in endothelial cells. Recent evidence suggests that HIF activity in endothelial cells is critical for angiogenesis and tumor progression. In this project, therefore, we want to focus on the influence of endothelial HIF hydroxylases on the vascularization, growth and metastasis of experimental tumors in mice. The activity of HIF hydroxylases will be modulated in tumor endothelial cells as well as in tumor cells by gain-of-function and loss-of-function experiments, both through virus-mediated gene transfer and transgenesis in mice. These studies will eventually lead to a better understanding of the interplay between tumor cells and the vasculature and may therefore be helpful in the development of new therapies.

• DFG-Verfahren: Schwerpunktprogramme
• Teilprojekt zu: SPP 1190: The tumor - vessel interface
• Beteiligte Person: Professor Dr. Ben Wielockx, Ph.D.